RT期刊文章SR电子T1 Fremanezumab对反应速率的影响,急性药物的使用,在情景性偏头痛患者和残疾之前失败了至少一个偏头痛预防药物(p2.10 - 001)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p2.10补充92 - 001签证官是15 A1保罗赢家A1 Rashmi Halker辛格A1约书亚·科恩A1 Ronghua杨A1保罗Yeung A1 Verena拉米雷斯Campos年2019 UL h首页ttp://www.ez-admanager.com/content/92/15_supplement/p2.10 - 001. -文摘AB目的:评估Fremanezumab在响应率的影响,在情景性偏头痛急性头痛药物的使用,和残疾(EM)失败的患者至少有一个事先预防偏头痛药物。背景:预防性药物治疗建议EM患者每月≥4天头痛。Fremanezumab,全人源化单克隆抗体(IgG2Δa)选择性目标降钙素相关基因肽(CGRP怎样),有效防止EM,但其有效性在之前的预防性药物治疗失败的患者是未知的。设计/方法:在这个阶段3、多中心、随机、双盲、安慰剂对照研究中,患者被随机分配比接受皮下fremanezumab季度(675 mg在基线和安慰剂在周4和8),每月fremanezumab(225毫克基线,星期4和8),或安慰剂(基线,周4和8)。分析失败的患者至少有一个事先预防偏头痛药物(由于缺乏有效性或无法忍受)。端点包括患者的比例≥每月平均减少50%的偏头痛天数,意味着从基线的月平均天数急性偏头痛头痛药物使用或残疾评估(MIDAS)得分在12周的治疗期。结果:更大比例的病人fremanezumab偏头痛天减少≥50%(季度:38%,P = 0.0115;月:42%,P = 0.0015)与安慰剂相比(18%)。Fremanezumab显著降低急性头痛药物使用的日子(季度(最小二乘均值变化):−3.1天;月:−3.4天)与安慰剂比较(−1.1天;同时,P < 0.0001)。Fremanezumab显著提高残疾,基于MIDAS的变化分数(季度:−24.7,P = 0.0006;月:−27.0,P < 0.0001)与安慰剂比较(−11.3)。Conclusions: Among EM patients with prior preventive migraine medication failure, fremanezumab was efficacious, reduced acute headache medication use, and improved disability, with effect sizes greater than those in the overall trial population.Disclosure: Dr. Winner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Supernus, Teva, Novartis, Avanir, and Promius. Dr. Halker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with WebMD/Medlink, Amgen, and Allergan. Dr. Halker has received personal compensation in an editorial capacity for Current Neurology & Neuroscience Reports. Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva Pharmaceuticals. Dr. Yang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Yeung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Gargano has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals.